MedWorm: Avastin

Bevacizumab: Intracranial haemorrhage: 2 case reports

Reactions — Sun, 05 Feb 2012 18:29:54 +0100

(Source: Reactions)

MedWorm Sponsor Message: Find the best January Sales in the UK.

In Vitro Coagulation Effects of Ophthalmic Doses of Bevacizumab

Journal of Ocular Pharmacology and Therapeutics — Fri, 03 Feb 2012 14:50:59 +0100

Journal of Ocular Pharmacology and Therapeutics , Vol. 0, No. 0. (Source: Journal of Ocular Pharmacology and Therapeutics)

Bevacizumab/irinotecan: Optic neuropathy: case report

Reactions — Thu, 02 Feb 2012 18:34:27 +0100

(Source: Reactions)

Bevacizumab: Eosinophilic gastroenteritis: case report

Reactions — Thu, 02 Feb 2012 18:34:27 +0100

(Source: Reactions)

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

Angiogenesis — Thu, 02 Feb 2012 18:09:18 +0100

Abstract Pharmacological inhibition of VEGF-A has proven to be effective in inhibiting angiogenesis and vascular leak associated with cancers and various eye diseases. However, little information is currently available on the binding kinetics and relative biological activity of various VEGF inhibitors. Therefore, we have evaluated the binding kinetics of two anti-VEGF antibodies, ranibizumab and bevacizumab, and VEGF Trap (also known as aflibercept), a novel type of soluble decoy receptor, with substantially higher affinity than conventional soluble VEGF receptors. VEGF Trap bound to all isoforms of human VEGF-A tested with subpicomolar affinity. Ranibizumab and bevacizumab also bound human VEGF-A, but with markedly lower affinity. The association rate for VEGF Trap bindin...

Bevacizumab and Sunitinib in Treating Patients With Solid Tumors

Kidney Cancer Association — Thu, 02 Feb 2012 04:27:33 +0100

Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab and sunitinib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving bevacizumab together with sunitinib may kill more tumor cells.02/01/2012 (Source: Kidney Cancer Association)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double‐blind study

Acta Ophthalmologica — Wed, 01 Feb 2012 05:00:00 +0100

Conclusions: Intravitreal triamcinolone proved to be more efficient in reducing DMO, providing longer lasting visual improvement, relative to bevacizumab. Eyes treated with triamcinolone had the highest percentage increase in IOP. Further studies are needed to corroborate these findings. (Source: Acta Ophthalmologica)

Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1‐year results of a prospective clinical study

Acta Ophthalmologica — Wed, 01 Feb 2012 05:00:00 +0100

Conclusion: The results of our 12‐month prospective study indicate that intravitreal bevacizumab alone has similar efficacy and safety to bevacizumab plus PDT for treatment of patients with neovascular AMD, even treatment‐naïve patients. The addition of PDT did not assist in reducing the required total number of bevacizumab injections. (Source: Acta Ophthalmologica)

Microperimetric changes after intravitreal bevacizumab injection for exudative age‐related macular degeneration

Acta Ophthalmologica — Wed, 01 Feb 2012 05:00:00 +0100

Conclusion: Intravitreal bevacizumab therapy induced a significant increase in mean retinal sensitivity and significant decrease in mean absolute scotoma size during 6 months. The MP1 microperimetry proved to be a valuable tool in the evaluation of functional benefit of exudative AMD therapy with intravitreal bevacizumab. (Source: Acta Ophthalmologica)

[Editorial] Ovarian cancer: breaking the silence

The Lancet Oncology — Wed, 01 Feb 2012 05:00:00 +0100

The heterogeneous nature of cancer makes it a very difficult disease to manage. Although great progress has been made against many types of cancer (as highlighted by recent mortality data from the American Cancer Society), treatment of others has shown little change in the past few decades. Ovarian cancer, for example, has traditionally lagged behind: recent research, however, is starting to provide a better outlook for women with this cancer. Two phase 3 clinical trials published in December, 2011, in the New England Journal of Medicine ( GOG018 and ICON7) showed that women with newly diagnosed advanced ovarian cancer given concomitant bevacizumab with a paclitaxel and carboplatin chemotherapy regimen following surgery, and then maintenance bevacizumab, had significantly longer progressio...

[Articles] Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial

The Lancet Oncology — Wed, 01 Feb 2012 05:00:00 +0100

The addition of bevacizumab to standard chemoradiation treatment for patients with nasopharyngeal carcinoma is feasible, and might delay the progression of subclinical distant disease. (Source: The Lancet Oncology)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Bevacizumab nasal spray: non‐invasive treatment of epistaxis in patients with Rendu‐Osler disease

The Laryngoscope — Wed, 01 Feb 2012 05:00:00 +0100

Conclusions:The intranasal spray application of 50mg bevacizumab was found to be an effective symptomatic treatment over a period of 2 months for patients with a pre‐treatment ESS of <7, with no adverse effects being noted. (Source: The Laryngoscope)

Laser bests injections for CSC

Modern Medicine — Wed, 01 Feb 2012 05:00:00 +0100

Photocoagulation performed using a micropulse subthreshold diode laser (MicroPulse, Iridex) was superior to intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy, according to a comparative, controlled, prospective study. (Source: Modern Medicine)

Bevacizumab for ROP

Ophthalmology — Wed, 01 Feb 2012 05:00:00 +0100

We read with interest the editorial by Moshfeghi and Berrocal regarding the Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP) study which reported the first randomized trial of anti-vascular endothelial growth factor (VEGF) treatment for ROP. The BEAT-ROP study reported a statistically significant reduction, by 54 weeks postmenstrual age (PMA), in treatment requiring recurrence of ROP in eyes treated with bevacizumab injection as compared with laser ablation. In their editorial, Moshfeghi and Berrocal note the eyes in the bevacizumab group had later mean onset of recurrence with large standard deviation and state concern for recurrence after the 54-week study endpoint. For zone 1 disease, this interval was 6.4±6.7 weeks after laser treatment but 19.2±8...

Author reply

Ophthalmology — Wed, 01 Feb 2012 05:00:00 +0100

We have carefully reviewed the commentary by Drs. Blair and Shapiro regarding the need for a change in retinopathy of prematurity (ROP) screening behavior both with respect to its duration and frequency following off-label administration of bevacizumab for zone I, stage 3+ ROP as advocated by the BEAT-ROP Study Group, and note that it highlights our own specific concerns outlined in our editorial. Specifically, we wrote, “Treatment with bevacizumab is not a one-and-done therapy.” (Source: Ophthalmology)

Expression of vascular Notch ligands Delta‐like 4 and Jagged‐1 in glioblastoma

Histopathology — Wed, 01 Feb 2012 05:00:00 +0100

Conclusions: In summary, Dll4 and Jag1 are expressed in glioblastoma vasculature. These data may define subsets of glioblastoma that might be sensitive (Dll4+/Jag1+) or resistant (Dll4+/Jag1–) to bevacizumab. Our data also suggest that anti‐Dll4 therapy should be evaluated experimentally in glioblastoma. (Source: Histopathology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Cancer: Drug drives cancer stem cells

Nature — Wed, 01 Feb 2012 05:00:00 +0100

Nature 482, 7383 (2012). doi:10.1038/482009c Cancer drugs that attack tumour-sustaining blood vessels may spur proliferation of the stem cells that contribute to the disease.One such drug, bevacizumab, fails to prolong the survival of patients with advanced breast cancers, and studies have shown that patients on similar drugs often relapse. (Source: Nature)

Intravitreous bevacizumab adult safety data: the evidence so far

Clinical and Experimental Ophthalmology — Wed, 01 Feb 2012 05:00:00 +0100

(Source: Clinical and Experimental Ophthalmology)

Macular Hole Progression after Intravitreal Bevacizumab for Hemicentral Retinal Vein Occlusion

International Journal of Photoenergy — Tue, 31 Jan 2012 11:10:23 +0100

Macular edema secondary to retinal vein occlusion is commonly being treated with off-label intravitreal bevacizumab with good outcomes. A significant reduction in macular edema and improvement in visual acuity is seen following such a treatment with no serious adverse effects. In the reported case, a full-thickness macular hole was noticed one month after intravitreal bevacizumab for macular edema secondary to hemicentral retinal vein occlusion. On a detailed review of the pre- and postoptical coherence tomography scans, it was realized that there was a preexisting stage 2-3 macular hole which was masked by the hemorrhages and edema at the fovea and the macular hole had progressed following the injection. (Source: International Journal of Photoenergy)

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Cancer Research — Tue, 31 Jan 2012 05:00:00 +0100

The protein kinase BRAF is a key component of the RAS–RAF signaling pathway which plays an important role in regulating cell proliferation, differentiation, and survival. Mutations in BRAF at codon 600 promote catalytic activity and are associated with 8% of all human (solid) tumors, including 8% to 10% of colorectal cancers (CRC). Here, we report the preclinical characterization of vemurafenib (RG7204; PLX4032; RO5185426), a first-in-class, specific small molecule inhibitor of BRAFV600E in BRAF-mutated CRC cell lines and tumor xenograft models. As a single agent, vemurafenib shows dose-dependent inhibition of ERK and MEK phosphorylation, thereby arresting cell proliferation in BRAFV600-expressing cell lines and inhibiting tumor growth in BRAFV600E bearing xenograft models. Because vemur...

Bevacizumab: Important Drug for NSCLCBevacizumab: Important Drug for NSCLC

Medscape Today Headlines — Mon, 30 Jan 2012 17:12:27 +0100

Dr. Mark Kris highlights the therapeutic benefits -- and toxicities -- associated with bevacizumab use in patients with non-small cell lung cancer. Medscape Hematology-Oncology (Source: Medscape Today Headlines)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Avastin May Extend Survival in Some Throat Cancers (CME/CE)

MedPage Today Meeting Coverage — Mon, 30 Jan 2012 15:03:13 +0100

PHOENIX (MedPage Today) -- Patients with advanced nasopharyngeal carcinoma achieved favorable overall survival when bevacizumab was added to upfront and adjuvant therapy, results of a preliminary cooperative group trial showed. (Source: MedPage Today Meeting Coverage)

FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study)

Japanese Journal of Clinical Oncology — Mon, 30 Jan 2012 05:00:00 +0100

We planned a multicenter randomized phase III study to evaluate the efficacy of appropriate dose of bevacizumab (5 or 10 mg/kg) with FOLFIRI in patients with advanced/metastatic colorectal cancer who have failed prior bevacizumab plus oxaliplatin-based therapy. The primary endpoint is progression-free survival. The secondary endpoints are the toxicity, response rate, time to treatment failure, overall survival, overall survival from the start of the first-line treatment and second progression-free survival (time duration from the initiation of the first-line treatment until progression after the protocol treatment). A total of 370 patients were considered to be appropriate for this trial. (Source: Japanese Journal of Clinical Oncology)

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high‐risk localized prostate cancer

Cancer — Sun, 29 Jan 2012 12:48:22 +0100

CONCLUSIONS:Neoadjuvant docetaxel and bevacizumab is safe, and results in reductions in both tumor volume and serum PSA, in men with high‐risk localized prostate cancer. The role of neoadjuvant chemotherapy in prostate cancer, and perioperative antiangiogenic therapy in general, requires further elucidation through ongoing and planned trials. Cancer 2012;. © 2012 American Cancer Society. (Source: Cancer)

Sudden Death Related to Toxicity in a Patient on Capecitabine and Irinotecan Plus Bevacizumab Intake: Pharmacogenetic Implications [DIAGNOSIS IN ONCOLOGY]

Journal of Clinical Oncology — Fri, 27 Jan 2012 05:00:00 +0100

(Source: Journal of Clinical Oncology)

Paclitaxel, Not Bevacizumab, Was Primarily Responsible for the Favorable Effects Seen in the RIBBON-2 Trial [CORRESPONDENCE]

Journal of Clinical Oncology — Fri, 27 Jan 2012 05:00:00 +0100

(Source: Journal of Clinical Oncology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trends

Pediatric Blood and Cancer — Fri, 27 Jan 2012 05:00:00 +0100

ConclusionBevacizumab‐related acute toxicity appears to be low in children, even in combination with irinotecan. Further prospective trials are required to confirm the hypothetical efficacy of bevacizumab and to assess the risk of long‐term toxicity especially in the youngest children. Pediatr Blood Cancer © 2012 Wiley Periodicals, Inc. (Source: Pediatric Blood and Cancer)

Lab Paradox May Explain Avastin's Effects (CME/CE)

MedPage Today Hematology/Oncology — Thu, 26 Jan 2012 21:13:07 +0100

(MedPage Today) -- Some anti-cancer agents may aid the growth of cancer stem cells -- paradoxically through the same mechanism they use to slow tumor growth, researchers reported. (Source: MedPage Today Hematology/Oncology)

Avastin fights early breast cancer in 2 studies: Will it be re-approved?

Health News: CBSNews.com — Thu, 26 Jan 2012 14:47:23 +0100

Avastin's approval for treating breast cancer was revoked by FDA in November, 2011 (Source: Health News: CBSNews.com)

Avastin may fight early breast cancers in certain women

CTV Health — Thu, 26 Jan 2012 13:15:19 +0100

Surprising results from two new studies may reopen debate about the value of Avastin for breast cancer. The drug helped make tumours disappear in certain women with early-stage disease, researchers found. (Source: CTV Health)

Breast Cancer Survival - Why Avastin And Sutent Don't Help

Health News from Medical News Today — Thu, 26 Jan 2012 12:00:00 +0100

Avastin and Sutent, two breast cancer drugs, do not lead to longer survival, probably because they encourage an increase in the number cancer stem cells in breast tumors, according to a study carried out on mice by researchers from the Michigan Comprehensive Cancer Center, and published in the Proceedings of the National Academy of Sciences (early edition). Even though Sutent (sunitinib) and Avastin (bevacizumab) do shrink breast cancer tumors and slow down the rate at which the cancer develops, their effects are short-lived - the cancers starts growing again and metastasizes (spreads)... (Source: Health News from Medical News Today)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Roche's Avastin helps colorectal cancer patients

Reuters: Health — Thu, 26 Jan 2012 07:39:39 +0100

ZURICH (Reuters) - Patients with advanced colorectal cancer who received Roche's Avastin live longer when they also receive the drug as part of their second round of treatment, the Swiss drugmaker said on Thursday, citing a late-stage study. (Source: Reuters: Health)

Avastin May Help Fight Early Breast Cancer

MedicineNet Cancer General — Thu, 26 Jan 2012 07:00:00 +0100

Title: Avastin May Help Fight Early Breast CancerCategory: Health NewsCreated: 1/26/2012 11:00:00 AMLast Editorial Review: 1/26/2012 (Source: MedicineNet Cancer General)

Avastin-based regimen extends survival when continued beyond initial treatment in patients with metastatic colorectal cancer

Roche Investor Update — Thu, 26 Jan 2012 06:00:00 +0100

First randomised phase III trial evaluating continued use of Avastin with chemotherapy after disease progression meets primary endpoint. Roche announced today that a phase III study (ML 18147) in metastatic colorectal cancer met its primary endpoint of overall survival. People who received Avastin® (bevacizumab) plus standard chemotherapy as initial treatment (so-called “first-line” treatment) for their metastatic colorectal cancer and then continued on Avastin with a different chemotherapy after their cancer progressed (so-called “second-line” treatment) lived significantly longer than people who received only chemotherapy in the second-line setting. (Source: Roche Investor Update)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

RCTs: Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer

NeLM - News — Thu, 26 Jan 2012 05:00:00 +0100

Source: N Engl J Med Area: News The efficacy of neoadjuvant chemotherapy, as measured by the rate of pathological complete response varies according to breast-cancer subtype. When anthracyclines, taxanes, and agents directed against HER2 (if indicated) are used, approximately 30 to 40% of all breast cancers that are HER2-positive or triple-negative are completely eradicated locally at the time of surgery. Long-term follow-up studies have shown a consistent correlation between pathological complete response and low rates of relapse and death among patients with these two subtypes of breast cancer. Two RCTs of neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer have been published in the New England Journal of Medicine (NEJM). The GeparQuinto phase...

Characteristics of Oral Mucosal Events Related to Bevacizumab Treatment.

The Oncologist — Thu, 26 Jan 2012 05:00:00 +0100

Conclusion. These characteristic clinical findings are consistent with geographic tongue. However, large prospective evaluations are necessary to confirm this potential relationship. If bevacizumab is indeed associated with geographic tongue, increased awareness may result in improved reporting and characterization of this particular adverse event. PMID: 22282905 [PubMed - as supplied by publisher] (Source: The Oncologist)

Avastin May Be Helpful Before Breast Cancer Surgery

Cancercompass News: Breast Cancer — Thu, 26 Jan 2012 00:00:00 +0100

However, it's not clear which patients would benefit, studies find (Source: Cancercompass News: Breast Cancer)

Studies: Avastin may fight early breast cancers

USATODAY.com Health — Wed, 25 Jan 2012 23:11:49 +0100

Avastin helped make tumors disappear in certain women with early-stage disease, according to a new study. (Source: USATODAY.com Health)

Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer

New England Journal of Medicine — Wed, 25 Jan 2012 22:00:16 +0100

New England Journal of Medicine, Volume 366, Issue 4, Page 310-320, January 2012. (Source: New England Journal of Medicine)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Fighting Fire with Fire: Rekindling the Bevacizumab Debate

New England Journal of Medicine — Wed, 25 Jan 2012 22:00:16 +0100

New England Journal of Medicine, Volume 366, Issue 4, Page 374-375, January 2012. (Source: New England Journal of Medicine)

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

New England Journal of Medicine — Wed, 25 Jan 2012 22:00:13 +0100

New England Journal of Medicine, Volume 366, Issue 4, Page 299-309, January 2012. (Source: New England Journal of Medicine)

Bevacizumab Shows Benefit in Nonmetastatic Breast CancerBevacizumab Shows Benefit in Nonmetastatic Breast Cancer

Medscape Today Headlines — Wed, 25 Jan 2012 22:00:00 +0100

Only months after the FDA revoked its metastatic breast cancer indication, the agent improved response in the neoadjuvant setting in 2 trials. Medscape Medical News (Source: Medscape Today Headlines)

Avastin May Be Helpful Before Breast Cancer Surgery

MedlinePlus Health News — Wed, 25 Jan 2012 22:00:00 +0100

However, it's not clear which patients would benefit, studies find Source: HealthDay Related MedlinePlus Pages: Breast Cancer, Cancer Chemotherapy (Source: MedlinePlus Health News)

Studies Reignite Debate over Avastin in Breast Cancer (CME/CE)

MedPage Today Public Health — Wed, 25 Jan 2012 21:06:05 +0100

(MedPage Today) -- Women with HER2-negative metastatic breast cancer had significantly higher rates of pathologic complete response when bevacizumab was added to neoadjuvant chemotherapy, two large clinical trials showed. (Source: MedPage Today Public Health)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Avastin, Sutent increase breast cancer stem cells, U-M study shows

EurekAlert! - Medicine and Health — Wed, 25 Jan 2012 05:00:00 +0100

(University of Michigan Health System) Cancer treatments designed to block the growth of blood vessels were found to increase the number of cancer stem cells in breast tumors in mice, suggesting a possible explanation for why these drugs don't lead to longer survival, according to a new study by researchers at the University of Michigan Comprehensive Cancer Center. (Source: EurekAlert! - Medicine and Health)

Avastin May Help Fight Early Breast Cancer

WebMD Health — Wed, 25 Jan 2012 05:00:00 +0100

Don't count out the drug Avastin as a breast cancer treatment just yet. But don't count it in, either. (Source: WebMD Health)

Biomarkers for antitumor activity of bevacizumab in gastric cancer models

BMC Cancer — Wed, 25 Jan 2012 05:00:00 +0100

Conclusions: VEGF levels and VEGF/bFGF ratios in tumors were related to bevacizumab sensitivity of the xenografts tested. Further clinical investigation into useful predictive markers for bevacizumab sensitivity is warranted. (Source: BMC Cancer)

Avastin May Be Helpful Before Breast Cancer Surgery

The Doctors Lounge - Oncology — Wed, 25 Jan 2012 05:00:00 +0100

However, it's not clear which patients would benefit, studies find (Source: The Doctors Lounge - Oncology)

NICE issues final guidance on cetuximab, bevacizumab and panitumumab for metastatic colorectal cancer (second-line)

NeLM - Guidelines — Wed, 25 Jan 2012 05:00:00 +0100

Source: NICE Area: Evidence > Guidelines NICE has issued final guidance on the use of cetuximab, bevacizumab and panitumumab for the second-line treatment of metastatic colorectal cancer (TA 242) which contains the following recommendations: . Cetuximab monotherapy or combination chemotherapy is not recommended for the treatment of people with metastatic colorectal cancer that has progressed after first-line chemotherapy. . Bevacizumab in combination with non-oxaliplatin (fluoropyrimidine-based) chemotherapy is not recommended for the treatment of people with metastatic colorectal cancer that has progressed after first-line chemotherapy. . Panitumumab monotherapy is not recommended for the treatment of people with metastatic colorectal c...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Systematic Review on Infusion Reactions Associated with Chemotherapies and Monoclonal Antibodies for Metastatic Colorectal Cancer.

Current Clinical Pharmacology — Wed, 25 Jan 2012 05:00:00 +0100

Conclusions: The incidence of IRs varies among different mAbs; and IRs may cause treatment disruption and require costly medical interventions. PMID: 22283610 [PubMed - as supplied by publisher] (Source: Current Clinical Pharmacology)

Factors associated with enlargement of chorioretinal atrophy after intravitreal bevacizumab for myopic choroidal neovascularization

Graefe's Archive for Clinical and Experimental Ophthalmology — Tue, 24 Jan 2012 07:53:15 +0100

Conclusions Our findings showed that eyes with a larger CNV at the baseline and longer follow-up period had a greater risk of developing a ChRA like non-treatment, even if IVB treatment was performed for mCNV. Content Type Journal ArticleCategory Retinal DisordersPages 1-9DOI 10.1007/s00417-011-1921-4Authors Riyo Uemoto, Department of Ophthalmology, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, JapanHoumei Nakasato-Sonn, Department of Ophthalmology, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, JapanTatsukata Kawagoe, Department of Ophthalmology, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, JapanMeguro Akir...

Boston keratoprosthesis restoring vision in an unusual case of end-stage limbal stem cell deficiency following exposure to Euphorbia latex

International Ophthalmology — Tue, 24 Jan 2012 07:33:56 +0100

We report the functional outcome of a patient who had undergone Boston keratoprosthesis type I for extensive ocular surface damage caused by latex of Euphorbia. The milky sap or latex of the Euphorbia plant is highly toxic and an irritant to the skin and eye. Damage to the eye ranges from mild to severe corneal edema, epithelial defects, anterior uveitis, secondary elevated intraocular pressure and, rarely, limbal stem cell deficiency with corneal neovascularization. A restrospective review was conducted of this patient for more than 1 year. During this period he was given subconjunctival bevacizumab injection to regress the corneal vascularization without much benefit, before finally performing Boston keratoprosthesis type I. The patient was evaluated periodically for both anato...

Ruthenium-106 brachytherapy and intravitreal bevacizumab for retinal capillary hemangioma

International Ophthalmology — Tue, 24 Jan 2012 07:33:55 +0100

Abstract The purpose of this study is to report a case of retinal capillary hemangioma treated with ruthenium-106 brachytherapy combined with intravitreal bevacizumab. A 58-year-old woman presented with blurred vision in her left eye for 15 days. Best-corrected visual acuity (BCVA) was counting fingers at 3 m in her left eye. Examination showed a peripheral endophytic retinal capillary hemangioma, with associated macular edema and diffuse hard exudates in a macular star pattern. B-scan ultrasonography revealed a solid, highly reflective retinal tumor measuring 7.1 × 7.5 mm in basal dimension and 3.5 mm in thickness. The hemangioma and macular edema were treated with ruthenium-106 brachytherapy (500 Gy) followed 1 month later with an ...

Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab

Medical Oncology — Tue, 24 Jan 2012 06:54:27 +0100

Abstract A 48-year-old man was referred to our hospital with the diagnosis of colon cancer with multiple hepatic metastases. After right hemicolectomy, the rapid progression of liver disease was treated with metronomic capecitabine and bevacizumab according to a study protocol. A gradual regression of metastatic lesions was observed during a 9-month treatment period. After conversion of liver disease to resectability, the histological examination disclosed the complete necrosis of all lesions, with the exception of small neoplastic foci inside a single nodule. The comparison of this type of histological findings with the classic sclero-hyaline pathological response, as well as its importance as indicator of response to antiangiogenic treatment, is discussed. Content Ty...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group

Annals of Oncology — Tue, 24 Jan 2012 05:00:00 +0100

Conclusions: Incorporation of bevacizumab into anthracycline-containing adjuvant therapy does not result in prohibitive cardiac toxicity. The definitive phase III trial (E5103) was activated with systematic and extensive cardiac monitoring to define the true impact of bevacizumab on cardiac function. (Source: Annals of Oncology)

Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience

Annals of Oncology — Tue, 24 Jan 2012 05:00:00 +0100

Conclusions: ICH with bevacizumab treatment in this population is rare and does not appear to increase its frequency over the baseline rate of ICH in a comparable population. Most bevacizumab-related ICH occurs into central nervous system tumors but spontaneous hemorrhages were seen. (Source: Annals of Oncology)

First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)

Annals of Oncology — Tue, 24 Jan 2012 05:00:00 +0100

Conclusions: The primary end point was surpassed showing promising activity of this bevacizumab/temozolomide combination with a favourable toxicity profile. Response and OS were significantly higher in BRAF wild-type patients. (Source: Annals of Oncology)

Bevacizumab in ovarian cancer

Nature Reviews Cancer — Tue, 24 Jan 2012 05:00:00 +0100

Nature Reviews Cancer 12, 83 (2012). doi:10.1038/nrc3213 Expression of vascular endothelial growth factor (VEGF) and angiogenesis correlate with ovarian cancer progression, and the VEGF-neutralizing monoclonal antibody bevacizumab has shown activity in Phase II trials in ovarian cancer. Two Phase III trials have now shown that bevacizumab may be beneficial when added to (Source: Nature Reviews Cancer)

Bevacizumab: Tractional retinal detachment: 25 case reports

Reactions — Mon, 23 Jan 2012 18:35:21 +0100

(Source: Reactions)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Bevacizumab for the Treatment of Retinopathy of PrematurityBevacizumab for the Treatment of Retinopathy of Prematurity

Medscape Today Headlines — Mon, 23 Jan 2012 16:16:35 +0100

How does intravitreal bevacizumab monotherapy compare with conventional laser therapy for the treatment of retinopathy of prematurity? Medscape Ophthalmology (Source: Medscape Today Headlines)

Bevacizumab (Avastin®) approved in the EU for ovarian cancer

NeLM - News — Mon, 23 Jan 2012 05:00:00 +0100

Source: Personal communication (Roche) Area: News The European Medicines Agency has approved an additional indication for bevacizumab (Avastin®) - for use in combination with carboplatin and paclitaxel for the front-line treatment of advanced (FIGO stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: NeLM - News)

Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity?

Acta Ophthalmologica — Mon, 23 Jan 2012 05:00:00 +0100

Conclusions: Given the high complication rate of the extensive laser treatment for zone I ROP, it is worth considering anti‐vascular endothelial growth factor treatment as an alternative therapy. Further knowledge concerning side effects and long‐term ocular and systemic outcome is warranted before this drug becomes general clinical practice. (Source: Acta Ophthalmologica)

Development of a Research Agenda for the Management of Metastatic Colorectal Cancer: Proceedings from a Multidisciplinary Research Consensus Panel

Journal of Vascular and Interventional Radiology : JVIR — Sat, 21 Jan 2012 08:07:49 +0100

This article reports the proceedings from this meeting. (Source: Journal of Vascular and Interventional Radiology : JVIR)

Avastin Doesn't Blind People, People Blind People

American Journal of Ophthalmology — Sat, 21 Jan 2012 03:51:05 +0100

Conclusions: Recommendations arising from a root cause analysis of infectious endophthalmitis outbreaks should focus on the procedures used by pharmacies to compound bevacizumab. Microbial contamination of bevacizumab-containing syringes prepared from the same vial of drug can be avoided by using a single vial of bevacizumab for each eye or by following strict adherence to United States Pharmacopoeia Chapter 797 requirements when compounding a single vial of bevacizumab into multiple syringes. (Source: American Journal of Ophthalmology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

An Outbreak of Streptococcus Endophthalmitis After Intravitreal Injection of Bevacizumab

American Journal of Ophthalmology — Sat, 21 Jan 2012 03:51:05 +0100

Conclusions: In this outbreak of endophthalmitis after intravitreal bevacizumab injection, Streptococcus mitis/oralis was cultured from the majority of patients and from all unused syringes. Visual outcomes were generally poor. The most likely cause of this outbreak was contamination during syringe preparation by the compounding pharmacy. (Source: American Journal of Ophthalmology)

Possible Short-term Changes of Aqueous Inflammatory Cytokines After Intravitreal Bevacizumab for Diabetic Macular Edema

American Journal of Ophthalmology — Sat, 21 Jan 2012 03:51:05 +0100

We read with great interest the article by Sohn and associates, “Changes in Aqueous Concentrations of Various Cytokines after Intravitreal Triamcinolone versus Bevacizumb for Diabetic Macular Edema.” They reported that only aqueous vascular endothelial growth factor (VEGF) was decreased significantly after intravitreal bevacizumab (IVB) treatment, but that aqueous levels of interleukin (IL)-6, IL-8, interferon-induced protein-10, monocyte chemotactic protein (MCP)-1, and platelet-derived growth factor-AA were not affected by IVB treatment. Previously, Funk and associates also reported that IVB resulted in a significant decrease of VEGF and that all other cytokines, including IL-8 and MCP-1, were not affected in patients with diabetic macular edema (DME). (Source: American Journal of Op...

Reply

American Journal of Ophthalmology — Sat, 21 Jan 2012 03:51:05 +0100

We appreciate the comments of Lee and Cho regarding short-term changes of aqueous inflammatory cytokines after intravitreal bevacizumab (IVB) for diabetic macular edema, and their remarks about possible acute alteration of associated cytokines after IVB are worth considering. (Source: American Journal of Ophthalmology)

Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease?

The British Journal of Ophthalmology — Fri, 20 Jan 2012 19:54:58 +0100

Authors: Manousaridis K, Talks J Abstract Anti-vascular endothelial growth factor (anti-VEGF) therapy has been shown to be effective at improving vision in patients with macular oedema due to diabetic retinopathy and vein occlusions, but blocking VEGF at least in theory could be detrimental to vascular integrity. For this reason, some patients with macular ischaemia were excluded from studies showing the effectiveness of therapy. A considerable number of patients present with mixed pathology of macular oedema and macular ischaemia and it is often impossible to determine the degree to which ischaemia accounts for decreased vision. In this review, the authors have dealt with the specific question of whether or not there is evidence to support potential worsening of the macular perfus...

Cost analysis comparing adjuvant epimacular brachytherapy with anti-VEGF monotherapy for the management of neovascular age-related macular degeneration

Eye — Fri, 20 Jan 2012 08:00:00 +0100

Authors: T L Jackson, L Kirkpatrick, G Tang & S Prasad (Source: Eye)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Avastin 25mg/ml concentrate for solution for infusion (Bevacizumab)-Revised SPC

NeLM - SPC Changes — Fri, 20 Jan 2012 05:00:00 +0100

Source: eMC (electronic Medicines Compendium) Area: Other Library Updates > SPC Changes There have been significant updates to several sections of the SPC, including the following: Changes to section 4.1- Therapeutic indication Avastin, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of advanced (FIGO stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer. Please refer to SPC link below for full information on all changes. (Source: NeLM - SPC Changes)

Ocular medicines in children: the regulatory situation related to clinical research

BMC Pediatrics - Latest articles — Fri, 20 Jan 2012 05:00:00 +0100

Conclusions: There is a pressing need for further research and clinical development in the pediatric ophthalmic area, where effective up-to-date treatments, and additional research and education on use in children, remain priorities. (Source: BMC Pediatrics - Latest articles)

Phase II Trial of Simple Oral Therapy with Capecitabine and Cyclophosphamide in Patients with Metastatic Breast Cancer: SWOG S0430.

The Oncologist — Fri, 20 Jan 2012 05:00:00 +0100

Conclusions. PFS, OS, and RR outcomes with capecitabine plus CPA compare favorably with those of capecitabine monotherapy and combination therapy with bevacizumab, sorafenib, or ixabepilone. The addition of these other agents to capecitabine does not improve OS time in MBC patients, and this single-arm study does not suggest that the addition of CPA to capecitabine has this potential in an unselected MBC population. When OS prolongation is the goal, clinicians should choose single-agent capecitabine. PMID: 22267853 [PubMed - as supplied by publisher] (Source: The Oncologist)

Erratum: A Phase 3 Trial of Bevacizumab in Ovarian Cancer

New England Journal of Medicine — Wed, 18 Jan 2012 22:00:08 +0100

New England Journal of Medicine, Volume 366, Issue 3, Page 284, January 2012. (Source: New England Journal of Medicine)

Reduced occurrence of programmed cell death and gliosis in the retinas of juvenile rabbits after shortterm treatment with intravitreous bevacizumab

Clinics — Wed, 18 Jan 2012 00:35:44 +0100

CONCLUSIONS: Bevacizumab appears to alter programmed cell death patterns and promote gliosis in the developing retinas of rabbits; therefore, it should be used with caution in developing eyes (Source: Clinics)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Bevacizumab/sorafenib/zoledronic acid: Osteonecrosis of the jaw and mandibular fracture in an elderly patient: case report

Reactions — Tue, 17 Jan 2012 19:08:18 +0100

(Source: Reactions)

Bevacizumab: Clubbing (first report), osteoarthropathy and lung diffusion disorder: 2 case reports

Reactions — Tue, 17 Jan 2012 19:08:18 +0100

(Source: Reactions)

Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies

JNCI — Tue, 17 Jan 2012 05:00:00 +0100

With the advent of targeted agents for the treatment of renal cell carcinoma (RCC), overall survival has improved, and patients are being treated continuously for increasingly long periods of time. This has raised challenges in the management of adverse events (AEs) associated with the six targeted agents approved in RCC—sorafenib, sunitinib, pazopanib, bevacizumab (in combination with interferon alpha), temsirolimus, and everolimus. Suggestions for monitoring and managing AEs have been published, but there are few consensus recommendations. In addition, there is a risk that patients will be subjected to multiple unnecessary investigations. In this review, we aimed to identify the level of supporting evidence for suggested AE management strategies to provide practical guidance on ess...

Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab.

Bulletin du Cancer — Tue, 17 Jan 2012 05:00:00 +0100

Authors: Vauleon E, Mesbah H, Gedouin D, Lecouillard I, Louvel G, Hamlat A, Riffaud L, Carsin B, Quillien V, Audrain O, Lesimple T Abstract Despite progress in the initial management of glioblastoma (GB), the vast majority of patients will experience recurrence within 2-3 years. The medical treatment of these recurrences is being modified by the use of antiangiogenic therapies. Twenty-four patients, who relapsed from GB after chemoradiation followed by adjuvant temozolomide in Rennes, were treated by conventional chemotherapy (nitrosourea) or by the combination of irinotecan and bevacizumab. In this retrospective analysis, overall survival from diagnosis of recurrence was significantly longer in patients treated with the combination of bevacizumab and irinotecan than with nitrosour...

Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer.

Clinical Cancer Research — Tue, 17 Jan 2012 05:00:00 +0100

ConclusionDual VEGF/EGFR inhibition can be integrated with CRT in locally advanced HNC, with efficacy that compares favorably to historical controls albeit with an increased risk of osteoradionecrosis. Pretreatment and early DCE-MRI may prospectively identify patients at high risk of failure. PMID: 22253412 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs

Cancer Cell — Tue, 17 Jan 2012 00:00:00 +0100

Astrid A.M. Van der Veldt, Mark Lubberink, Idris Bahce, Maudy Walraven, Michiel P. de Boer, Henri N.J.M. Greuter, N. Harry Hendrikse, Jonas Eriksson, Albert D. Windhorst, Pieter E. Postmus, Henk M. Verheul, Erik H. Serné, Adriaan A. Lammertsma, Egbert F. Smit. Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in cancer patients. It is assumed that anti-angiogenic drugs, such as bevacizumab, transiently normali.... (Source: Cancer Cell)

Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease?

British Journal of Ophthalmology — Mon, 16 Jan 2012 05:00:00 +0100

Anti-vascular endothelial growth factor (anti-VEGF) therapy has been shown to be effective at improving vision in patients with macular oedema due to diabetic retinopathy and vein occlusions, but blocking VEGF at least in theory could be detrimental to vascular integrity. For this reason, some patients with macular ischaemia were excluded from studies showing the effectiveness of therapy. A considerable number of patients present with mixed pathology of macular oedema and macular ischaemia and it is often impossible to determine the degree to which ischaemia accounts for decreased vision. In this review, the authors have dealt with the specific question of whether or not there is evidence to support potential worsening of the macular perfusion and visual function after anti-VEGF treatment ...

Use of pneumatic nebulization and laser ablation-inductively coupled plasma-mass spectrometry to study the distribution and bioavailability of an intraperitoneally administered Pt-containing chemotherapeutic drug.

Analytical and Bioanalytical Chemistry — Sun, 15 Jan 2012 05:00:00 +0100

Authors: Gholap D, Verhulst J, Ceelen W, Vanhaecke F Abstract Quadrupole-based inductively coupled-mass spectrometry (ICP-MS) with pneumatic nebulization as a means of sample introduction was employed for quantification of platinum in blood and tissue samples of rats with peritoneal carcinomatosis, receiving intraperitoneal treatment with the Pt-containing chemotherapeutic drug oxaliplatin, and in the perfusate solution used for this purpose. The Pt levels were measured for various treatment conditions, i.e., with and without supporting treatment with the drug bevacizumab and at two different temperatures. Limits of detection obtained for platinum in blood and tissue samples were 0.3 and 2.0 pg g (,) (-1) respectively. Evaluation of drug pe...

Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study

BioMed Central — Sat, 14 Jan 2012 05:00:00 +0100

Conclusions: IV bevacizumab was well tolerated in selected HCC subjects undergoing TACE, and appeared to diminish neovessel formation at week 14.Trial registrationClinicalTrials.gov NCT00049322. (Source: BioMed Central)

Bevacizumab: Osteonecrosis of the humeral head: case report

Reactions — Fri, 13 Jan 2012 23:22:43 +0100

(Source: Reactions)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Bevacizumab: Hypertension, and first report of amenorrhoea and migraines: 2 case reports

Reactions — Fri, 13 Jan 2012 23:22:43 +0100

(Source: Reactions)

Bevacizumab/irinotecan: Skin necrosis: case report

Reactions — Fri, 13 Jan 2012 23:22:43 +0100

(Source: Reactions)

Treatment of macular edema due to branch retinal vein occlusion with single or multiple intravitreal injections of bevacizumab

Japanese Journal of Ophthalmology — Fri, 13 Jan 2012 16:50:30 +0100

Conclusion Baseline VA and IS/OS line grade at 4 weeks may be predictive factors for final VA. Content Type Journal ArticleCategory Clinical InvestigationPages 1-6DOI 10.1007/s10384-011-0114-3Authors Tatsuya Yunoki, Department of Ophthalmology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0194 JapanAkio Miyakoshi, Department of Ophthalmology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0194 JapanTomoko Nakamura, Department of Ophthalmology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0194 JapanKazuya Fujita, Department of Ophthalmology, Graduate School of Medicine and Pharmaceutical ...

Evaluation of Efficacy and Safety of Bevacizumab Combined with Chemotherapy  for Chinese Patients with Advanced Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer — Fri, 13 Jan 2012 13:20:50 +0100

Conclusion Bevacizumab combined with carboplatin-based chemotherapy may be well tolerated and beneficial for Chinese patients with non-squamous NSCLC. DOI: 10.3779/j.issn.1009-3419.2012.01.02 (Source: Chinese Journal of Lung Cancer)

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)

British Journal of Cancer AOP — Thu, 12 Jan 2012 05:00:00 +0100

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC) British Journal of Cancer advance online publication, January 12, 2012. doi:10.1038/bjc.2011.594 Authors: J Souglakos, N Ziras, S Kakolyris, I Boukovinas, N Kentepozidis, P Makrantonakis, S Xynogalos, Ch Christophyllakis, Ch Kouroussis, L Vamvakas, V Georgoulias & A Polyzos (Source: British Journal of Cancer AOP)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy

The Pharmacogenomics Journal — Tue, 10 Jan 2012 05:00:00 +0100

Authors: A Pohl, A El-Khoueiry, D Yang, W Zhang, G Lurje, Y Ning, T Winder, S Hu-Lieskoven, S Iqbal, K D Danenberg, M Kahn, J-L Teo, J Shriki, J Stebbing & H-J Lenz (Source: The Pharmacogenomics Journal)

First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study.

The Oncologist — Tue, 10 Jan 2012 05:00:00 +0100

Conclusion. Although the noninferiority of bevacizumab versus XELOX plus bevacizumab cannot be confirmed, we can reliably exclude a median PFS detriment >3 weeks. This study suggests that maintenance therapy with single-agent bevacizumab may be an appropriate option following induction XELOX plus bevacizumab in mCRC patients. PMID: 22234633 [PubMed - as supplied by publisher] (Source: The Oncologist)

Head and neck cancer: Bevacizumab an option for nasopharyngeal carcinoma?

Nature Clinical Practice Oncology — Tue, 10 Jan 2012 05:00:00 +0100

Nature Reviews Clinical Oncology 9, 66 (2012). doi:10.1038/nrclinonc.2011.209 A recent phase II trial has shown that bevacizumab is tolerated by patients with nasopharyngeal carcinoma. The trial assessed patients with grade IIB–IVB disease and combined treatment with bevacizumab and cisplatin with intensity-modulated radiation therapy. There were no grade 5 adverse events, which was one (Source: Nature Clinical Practice Oncology)

Avastin loses breast cancer indication

Nature Biotechnology — Mon, 09 Jan 2012 05:00:00 +0100

Nature Biotechnology 30, 6 (2012). doi:10.1038/nbt0112-6a Author: Karen Carey (Source: Nature Biotechnology)

Evaluation of the Clinical Relevance of Body Composition Parameters in Patients With Cancer Metastatic to the Liver Treated With Hepatic Arterial Infusion Chemotherapy.

Nutrition and Cancer — Mon, 09 Jan 2012 05:00:00 +0100

In conclusion, body composition was not significantly associated with toxicities or survival in our small sample. PMID: 22229660 [PubMed - as supplied by publisher] (Source: Nutrition and Cancer)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

AVASTIN (Bevacizumab) Injection, Solution [Genentech, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 09 Jan 2012 05:00:00 +0100

Updated Date: Jan 9, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Intravitreal Inoculation of Cotton After Bevacizumab (Avastin) Injection [Ophthalmic Images]

Archives of Opthalmology — Mon, 09 Jan 2012 05:00:00 +0100

(Source: Archives of Opthalmology)

Adjuvant bevacizumab could delay ovarian cancer progression

MedWire News - Ob/Gyn — Mon, 09 Jan 2012 03:39:41 +0100

Treatment with bevacizumab as an addition to standard chemotherapy could delay the progression of advanced epithelial ovarian cancer, two studies in The New England Journal of Medicine suggest. (Source: MedWire News - Ob/Gyn)

Avastin 'delays ovarian cancer growth'

Nursing Times Breaking News — Sun, 08 Jan 2012 00:28:00 +0100

Women with advanced ovarian cancer may be offered new hope by Avastin’s ability to starve tumours of blood. (Source: Nursing Times Breaking News)

Incorporating bevacizumab into nasopharyngeal treatment safe, feasible

HemOncToday.com — Fri, 06 Jan 2012 16:23:00 +0100

Lee NY. Lancet Oncol. 2011;doi:10.1016/S1470-2045(11)70303-5. (Source: HemOncToday.com)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Iron Deficiency Anemia Related to Hereditary Hemorrhagic Telangiectasia: Response to Treatment With Bevacizumab.

The American Journal of the Medical Sciences — Fri, 06 Jan 2012 05:00:00 +0100

Iron Deficiency Anemia Related to Hereditary Hemorrhagic Telangiectasia: Response to Treatment With Bevacizumab. Am J Med Sci. 2012 Jan 6; Authors: Fleagle JM, Bobba RK, Kardinal CG, Freter CE Abstract Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant condition associated with arteriovenous malformations (AVMs) or telangiectasias of the pulmonary, gastrointestinal or hepatic circulations. The authors present a case of a 52-year-old woman with a known diagnosis of HHT who presented for evaluation of anemia. She had an extensive history of iron sucrose infusions, frequent blood transfusions and hospitalizations for anemia related to gastrointestinal bleeding and epistaxis. The patient was treated with bevacizumab at a dose of 5 mg/kg infusion every 2 we...

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours

British Journal of Cancer AOP — Thu, 05 Jan 2012 05:00:00 +0100

Authors: E Dean, M R Middleton, T Pwint, H Swaisland, J Carmichael, P Goodege-Kunwar & M Ranson (Source: British Journal of Cancer AOP)

RCTs of bevacizumab in ovarian cancer report improved PFS

NeLM - News — Thu, 05 Jan 2012 05:00:00 +0100

Source: N Engl J Med Area: News Vascular endothelial growth factor is a key promoter of angiogenesis and disease progression in epithelial ovarian cancer. Bevacizumab, a vascular endothelial growth factor inhibitor, has shown activity in this condition. Two RCTs published in the New England Journal of Medicine have evaluated its use in the treatment of ovarian cancer. The first study conducted by the International Collaboration on Ovarian Neoplasms (ICON7) involved 1528 women (median age 57 years), 90% of whom had epithelial ovarian cancer, 69% serous histologic type, 9% high-risk early-stage disease, 30% high risk for progression, and 70% stage IIIC or IV. They were randomised to carboplatin (AUC 5 or 6) and paclitaxel (175mg/m2), given every 3 weeks for 6 cycles, or to ...

Progression-Free Survival Of Patients With Advanced Ovarian Cancer Extended By Targeted Therapy

Health News from Medical News Today — Wed, 04 Jan 2012 08:00:00 +0100

Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer. A new phase 3 clinical trial conducted by the Gynecologic Oncology Group (GOG) showed that a targeted therapy called bevacizumab (Avastin) effectively delayed the progression of advanced ovarian cancer. Patients with newly diagnosed advanced ovarian cancer now typically undergo surgery and chemotherapy, but the new research suggests an additional avenue of treatment... (Source: Health News from Medical News Today)

Bevacizumab delayed progression of epithelial ovarian cancer

HemOncToday.com — Tue, 03 Jan 2012 08:38:00 +0100

Burger RA. N Engl J Med. 2011;365:2473-2483. (Source: HemOncToday.com)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer

Angiogenesis — Mon, 02 Jan 2012 16:46:32 +0100

Conclusions The schedule of neoadjuvant therapy tested was safe and active. Pre-treatment vessel density by the panendothelial marker anti CD-34 antibody, post-treatment Ki-67 labeling index and VEGFR-2 expression were significantly associated to residual tumor area. The biomarkers correlations warrant further evaluation in prospective clinical trials. Content Type Journal ArticleCategory Original PaperPages 1-10DOI 10.1007/s10456-011-9250-0Authors Giampietro Gasparini, Unità Operativa Complessa di Oncologia Medica, Azienda Complesso Ospedaliero di Rilevanza Nazionale “S. Filippo Neri”, Via G. Martinotti, 20, 00135 Rome, ItalyFrancesco Torino, Unità Operativa Complessa di Oncologia Medica, Azienda Complesso Ospedaliero di Rilevanza Nazionale “S. Filippo Neri...

[Correspondence] Chemotherapy for colorectal cancer

The Lancet Oncology — Sun, 01 Jan 2012 05:00:00 +0100

We read with interest the FFCD trial by Ducreux and colleagues in The Lancet Oncology. This trial was the first of its type to expose patients to all standard chemotherapy drugs (except bevacizumab), which was a weakness in applying the results of previous sequential versus combination trials to current chemotherapy use. However, several aspects of the trial could affect the interpretation and applicability of the study. After first-line treatment the sequential group was receiving doublet chemotherapy. (Source: The Lancet Oncology)

Use of bevacizumab in the treatment of metastatic colorectal cancer.

British Journal of Hospital Medicine — Sun, 01 Jan 2012 05:00:00 +0100

Authors: Raouf S, Bridgewater J, Ellis R, Ferry D, Hill M, Wasan H Abstract The Cancer Drugs Fund may allow more patients in England access to clinically effective cancer therapies. In this article oncologists already familiar with the clinical evidence, and experienced in treating with bevacizumab, share practical recommendations on optimal first-line use of this treatment for metastatic colorectal cancer. PMID: 22241406 [PubMed - in process] (Source: British Journal of Hospital Medicine)

Prolonged activity of bevacizumab in adenocarcinoma of the lung with multiple brain metastases

Medical Oncology — Fri, 30 Dec 2011 16:43:30 +0100

We present long-term disease treatment in a 60-year-old woman having greater than thirty brain metastases of NSCLC adenocarcinoma with a mutant allele of EGFR treated with differing chemotherapies including erlotinib, but disease response in the brain only with bevacizumab. Although initially restricted in use, increasing clinical reports have demonstrated safety of bevacizumab use in brain-involved cancer patients. Our case highlights that disease response to bevacizumab is similar in the brain to systemic disease and likely overcomes anatomical barriers that can limit other therapeutic agents. Content Type Journal ArticleCategory Short CommunicationPages 1-4DOI 10.1007/s12032-011-0148-xAuthors Oana C. Danciu, Department of Medicine, Section of Hematology/Oncology, University ...

Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study)

Medical Oncology — Fri, 30 Dec 2011 16:43:26 +0100

Abstract The efficacy of bevacizumab combined with infusional 5-fluorouracil/leucovorin (5-FU/LV) plus irinotecan (FOLFIRI) as the second-line treatment for metastatic colorectal cancer (mCRC) has not been fully clarified, although bevacizumab combined with infusional 5-FU/LV plus oxaliplatin (FOLFOX) in the second-line setting has demonstrated a survival benefit. We investigated the efficacy of bevacizumab plus FOLFIRI in mCRC patients who failed oxaliplatin-containing regimens without bevacizumab. Patients who received bevacizumab plus FOLFIRI or bevacizumab plus FOLFOX as second-line chemotherapy between July 2007 and March 2008 were registered (trial registration: UMIN000001547). Patient background data and progression-free survival (PFS), overall survival (OS), respon...

MedWorm Sponsor Message: Find the best January Sales in the UK.

VEGF-A/VEGFR-2 Signaling Plays an Important Role for the Motility of Pancreas Cancer Cells

Annals of Surgical Oncology — Fri, 30 Dec 2011 06:50:01 +0100

Conclusions VEGF-A/VEGFR-2 signaling plays an important role in inducing invasion and migration of pancreatic cancer cells. Content Type Journal ArticleCategory Translational Research and BiomarkersPages 1-11DOI 10.1245/s10434-011-2181-6Authors Yosuke Doi, Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, JapanMasakazu Yashiro, Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, JapanNobuya Yamada, Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, JapanRyosuke Amano, Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, JapanSatoru Noda, Department of Surgical Oncology, Osaka City University Graduate School of Medi...

Management of peripheral polypoidal choroidal vasculopathy with intravitreal bevacizumab and indocyanine green angiography-guided laser photocoagulation

Indian Journal of Ophthalmology — Fri, 30 Dec 2011 05:00:00 +0100

Pukhraj Rishi, Atheeswar Das, Pallavi Sarate, Ekta RishiIndian Journal of Ophthalmology 2012 60(1):60-63A 69-year-old lady presented with complaints of decreased vision in left eye since one month. Best Corrected Visual Acuity (BCVA) was 6/18 in that eye. Fundus examination revealed non-central geographic atrophy and soft drusens at macula in both eyes. Temporal periphery of left eye revealed subretinal exudates with altered sub-RPE hemorrhage mimicking peripheral exudative hemorrhagic chorioretinopathy (PEHCR). Fundus Fluorescein Angiogram showed window defects at macula and blocked fluorescence at temporal periphery in left eye. However, Indocyanine green angiography (ICGA) revealed active peripheral choroidal polyps. The patient was successfully treated with intravitreal bevacizumab and...

Bevacizumab in Clinical Practice: Prescribing Appropriateness Relative to National Indications and Safety.

The Oncologist — Fri, 30 Dec 2011 05:00:00 +0100

Authors: Bonifazi M, Rossi M, Moja L, Scigliano VD, Franchi M, La Vecchia C, Zocchetti C, Negri E Abstract AbstractThe aim of this study was to describe the clinical use of bevacizumab in Lombardy (9.5 million inhabitants), Italy, during 2006-2007 in patients with metastatic colorectal cancer (mCRC) to evaluate compliance with the Italian Medicine Agency (AIFA) indications, the incidence of adverse events, and the survival rate.We performed computerized record linkage among three different Lombardy health care databases: File F registry, Regional discharge database, and Registry Office records. Patients were classified into approved and off-label uses according to the AIFA indications.Treatment with bevacizumab was administered to 780 patients, of whom 81.7% (n = 637) had mCRC. Amo...

Drug Falls Short In Cancer Study

WSJ.com: Health — Thu, 29 Dec 2011 23:42:05 +0100

Roche's Avastin failed to lengthen ovarian cancer patients' lives but stalled progression of the disease for a few months in studies reported in the New England Journal of Medicine. (Source: WSJ.com: Health)

Avastin unlikely to get ovarian cancer approval after disappointing studies

Health News: CBSNews.com — Thu, 29 Dec 2011 16:29:57 +0100

Avastin gave more side effects, did not improve survival for most ovarian cancer patients (Source: Health News: CBSNews.com)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Avastin disappoints, teddy bears recalled

USATODAY.com Health — Thu, 29 Dec 2011 15:46:00 +0100

Avastin has modest results against ovarian cancer, Build-A-Bear recalls a teddy bear and breastfeeding women protest at Target stores. (Source: USATODAY.com Health)

Avastin ovarian cancer studies get mixed results

bizjournals.com Health Care:Biotechnology headlines — Thu, 29 Dec 2011 15:14:06 +0100

Two studies found that Genentech's cancer drug Avastin failed to prolong life on patients, but kept their disease from worsening for a time, the Washington Post reports. The two studies released Thursday showed the drug could slow the growth of ovarian cancer when added to chemotherapy, news that was welcomed by patient advocates, who point to the lack of new treatments for the disease. With the mixed results, though, Genentech said it was unlikely at this time to seek Food and Drug Administration approval of Avastin for ovarian cancer. (Source: bizjournals.com Health Care:Biotechnology headlines)

Avastin disappoints against ovarian cancer

USATODAY.com Health — Thu, 29 Dec 2011 15:08:04 +0100

The drug won approval in Europe for advanced ovarian cancer. But its maker has no immediate plans to seek approval in the United States. (Source: USATODAY.com Health)

Targeted therapy extends progression-free survival of patients with advanced ovarian cancer

ScienceDaily Headlines — Thu, 29 Dec 2011 14:18:18 +0100

Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer. A new Phase 3 clinical trial has shown that a targeted therapy called bevacizumab (Avastin) effectively delayed the progression of advanced ovarian cancer. Patients with newly diagnosed advanced ovarian cancer now typically undergo surgery and chemotherapy, but the new research suggests an additional avenue of treatment. (Source: ScienceDaily Headlines)

Ovarian Cancer Study Proves Drug Delays Disease Progression, May Improve Survival

Health News from Medical News Today — Thu, 29 Dec 2011 09:00:00 +0100

Treating ovarian cancer with the drug bevacizumab ("Avastin") delays the disease and may also improve survival, show the results of an international clinical trial co-led by Drs. Amit Oza of the Princess Margaret Cancer Program, University Health Network and Timothy Perren, St James's Institute of Oncology, Leeds, UK. The findings, published today in the New England Journal of Medicine, report that the drug halted the cancer's return for two months overall... (Source: Health News from Medical News Today)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Avastin Delays Ovarian Cancer Progression

MedicineNet Cancer General — Thu, 29 Dec 2011 07:00:00 +0100

Title: Avastin Delays Ovarian Cancer ProgressionCategory: Health NewsCreated: 12/29/2011 11:01:00 AMLast Editorial Review: 12/29/2011 (Source: MedicineNet Cancer General)

BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma [Melanoma]

Journal of Clinical Oncology — Thu, 29 Dec 2011 05:00:00 +0100

Conclusion The study did not meet the primary objective of statistically significant improvement in PFS with the addition of bevacizumab to carboplatin plus paclitaxel. A larger phase III study will be necessary to determine whether there is benefit to the addition of bevacizumab to carboplatin plus paclitaxel in this disease setting. (Source: Journal of Clinical Oncology)

Bevacizumab Increases Progression Free Survival

OCRF News — Thu, 29 Dec 2011 05:00:00 +0100

Research shows that bevacizumab increases progression free survival in ovarian cancer patients. In the Dec 29, 2011 issue of the New England Journal of Medicine, researchers published results from two large phase III trials of the drug bevacizumab, which indicate that the anti-angiogenesis drug increases progression free survival in newly-diagnosed patients with ovarian cancer. Results from the ICON7 trial demonstrated a 1.5 month increase in PFS, while the GOG218 trial showed a 4 month boost in PFS. Along with results from the OCEANS trial presented at the 2011 ASCO meeting, which also showed an increase in progression free survival, the two studies published today add to the body of research suggesting bevacizumab may be a useful frontline treatment for women with advanced...

Year in Health: Less is more in cancer care, drug shortages

USATODAY.com Health — Thu, 29 Dec 2011 04:09:45 +0100

Experts urge fewer tests for prostate cancer, no Avastin for breast cancer, and HPV shots for all kids. (Source: USATODAY.com Health)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Avastin can stabilize tumors in ovarian cancer, studies find

Los Angeles Times - Science — Thu, 29 Dec 2011 01:35:00 +0100

Two independent groups working with advanced-stage cases say the drug extended the period before the disease worsened by more than 3.5 months.Avastin can stabilize tumors in women suffering from advanced-stage ovarian cancer, extending the period before the disease worsens by more than 3.5 months, according to the results of two large, international clinical trials conducted by separate research teams. (Source: Los Angeles Times - Science)

Avastin May Help Some With Ovarian Cancer: Studies

The Doctors Lounge - Oncology — Wed, 28 Dec 2011 23:00:00 +0100

Survival without disease getting worse rose slightly, but benefit on overall survival remains unclear (Source: The Doctors Lounge - Oncology)

Little benefit of Avastin against ovarian cancer: studies

CTV Health — Wed, 28 Dec 2011 22:47:26 +0100

Avastin, the blockbuster drug that just lost approval for treating breast cancer, now looks disappointing against ovarian cancer, too. Two studies found it did not improve survival for most of these patients and kept their disease from worsening for only a few months. (Source: CTV Health)

Avastin Improves PFS in Ovarian CancerAvastin Improves PFS in Ovarian Cancer

Medscape Today Headlines — Wed, 28 Dec 2011 22:00:39 +0100

Two phase 3 trials have indicated that bevacizumab slows disease progression in ovarian cancer. Medscape Medical News (Source: Medscape Today Headlines)

Bevacizumab Improves PFS in Ovarian Cancer Bevacizumab Improves PFS in Ovarian Cancer

Medscape Medical News Headlines — Wed, 28 Dec 2011 22:00:39 +0100

Two phase 3 trials have indicated that bevacizumab slows disease progression in ovarian cancer. Medscape Medical News (Source: Medscape Medical News Headlines)

MedWorm Sponsor Message: Find the best January Sales in the UK.

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

New England Journal of Medicine — Wed, 28 Dec 2011 22:00:22 +0100

New England Journal of Medicine, Volume 365, Issue 26, Page 2484-2496, December 2011. (Source: New England Journal of Medicine)

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

New England Journal of Medicine — Wed, 28 Dec 2011 22:00:18 +0100

New England Journal of Medicine, Volume 365, Issue 26, Page 2473-2483, December 2011. (Source: New England Journal of Medicine)

Avastin Delays Ovarian Cancer Progression

WebMD Health — Wed, 28 Dec 2011 21:00:20 +0100

The cancer drug Avastin helped stop the spread of ovarian cancer in patients with an advanced form of the disease, two major studies have found. But it is not clear if it helps patients to live longer than other cancer treatments. (Source: WebMD Health)

Bevacizumab Delays Progression of Ovarian Cancer (CME/CE)

MedPage Today Primary Care — Wed, 28 Dec 2011 21:00:00 +0100

(MedPage Today) -- Bevacizumab (Avastin) modestly improved progression-free survival in ovarian cancer, two large randomized trials found. (Source: MedPage Today Primary Care)

Bevacizumab Delays Progression of Ovarian Cancer (CME/CE, with audio)

MedPage Today Hematology/Oncology — Wed, 28 Dec 2011 21:00:00 +0100

(MedPage Today) -- Bevacizumab (Avastin) modestly improved progression-free survival in ovarian cancer, two large randomized trials found. (Source: MedPage Today Hematology/Oncology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors

Journal of Neuro-Oncology — Wed, 28 Dec 2011 06:53:39 +0100

We report our experience with bevacizumab (BEV), a VEGF targeting antibody, following failure of a VEGF receptor targeting tyrosine kinase inhibitor (TKI). We retrospectively identified patients treated on clinical trials with VEGFR–TKIs for recurrent GBM followed by BEV at next recurrence. Survival was estimated by the Kaplan–Meier method. Fourteen patients were identified (six women; median age 57). All received VEGFR–TKIs (sunitinib 11, cediranib 2, sorafenib 1) then BEV at next recurrence. There were no radiographic responses to VEGFR–TKIs; best response was stable disease in 50% (7/14). Patients received BEV alone (21%, 3/14) or in combination with chemotherapy (79%, 11/14). On BEV, 29% (4/14) had a partial response, and 36% (5/14) stabilized. Of evaluable patients, 42% ...

Targeted therapy extends progression-free survival of patients with advanced ovarian cancer

EurekAlert! - Medicine and Health — Wed, 28 Dec 2011 05:00:00 +0100

(Fox Chase Cancer Center) Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer. A new Phase 3 clinical trial conducted by the Gynecologic Oncology Group showed that a targeted therapy called bevacizumab (Avastin) effectively delayed the progression of advanced ovarian cancer. Patients with newly diagnosed advanced ovarian cancer now typically undergo surgery and chemotherapy, but the new research suggests an additional avenue of treatment. (Source: EurekAlert! - Medicine and Health)

Ovarian cancer study proves drug delays disease progression, may improve survival

EurekAlert! - Medicine and Health — Wed, 28 Dec 2011 05:00:00 +0100

(University Health Network) Treating ovarian cancer with the drug bevacizumab ("Avastin") delays the disease and may also improve survival, show the results of an international clinical trial co-led by Drs. Amit Oza of the Princess Margaret Cancer Program, University Health Network and Timothy Perren, St James's Institute of Oncology, Leeds, UK. (Source: EurekAlert! - Medicine and Health)

Evaluation of combined bevacizumab plus irinotecan therapy in brain tumors using magnetic resonance imaging measures of relative cerebral blood volume

Magnetic Resonance in Medicine — Wed, 28 Dec 2011 05:00:00 +0100

AbstractFrequently, bevacizumab is combined with chemotherapeutics such as irinotecan, motivated by studies showing improved clinical outcomes compared with historical controls. However, no systematic studies have been performed to determine if and how these drugs should be combined for optimal therapeutic response. The purpose of this study was to characterize the temporal combinations of bevacizumab and irinotecan by measuring the contrast‐agent enhanced tumor volumes and relative cerebral blood volume using dynamic susceptibility contrast imaging. The studies, performed in the U87 brain tumor model, show a vascular normalization window with bevacizumab monotherapy and are consistent with clinical indications of no additional benefit in the addition of irinotecan to bevacizumab therapy...

2013 results to show if bevacizumab (Avastin) prolongs life in ovarian cancer

Modern Medicine — Wed, 28 Dec 2011 05:00:00 +0100

NEW YORK (Reuters Health) - The coauthor of a study that helped convince the European Commission on Friday to approve bevacizumab (Avastin) as an initial post-surgical treatment for advanced ovarian cancer predicted that some doctors may be reluctant to use the drug until mortality data become available in 2013. (Source: Modern Medicine)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Avastin May Help Some With Ovarian Cancer: Studies

Cancercompass News: Breast Cancer — Wed, 28 Dec 2011 00:00:00 +0100

Survival without disease getting worse rose slightly, but benefit on overall survival remains unclear (Source: Cancercompass News: Breast Cancer)

A double‐blind, randomized, placebo‐controlled, phase 2 study of maintenance enzastaurin with 5‐fluorouracil/leucovorin plus bevacizumab after first‐line therapy for metastatic colorectal cancer

Cancer — Tue, 27 Dec 2011 05:00:00 +0100

CONCLUSIONS:Enzastaurin combined with bevacizumab‐based therapy is tolerable, but does not improve PFS during maintenance therapy in patients with MCRC compared with bevacizumab‐based therapy alone. Cancer 2011. © 2011 American Cancer Society. (Source: Cancer)

Effectiveness of Liver Metastasectomies in Patients With Metastatic Colorectal Cancer Treated With FIr-B/FOx Triplet Chemotherapy Plus Bevacizumab.

Clinical Colorectal Cancer — Tue, 27 Dec 2011 05:00:00 +0100

Conclusion: The FIr-B/FOx regimen may increase the resection rate of liver metastases and improve clinical outcome of patients with liver-only MCRC. PMID: 22206922 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)

Abrogation of Gli3 expression suppresses the growth of colon cancer cells via activation of p53.

Experimental Cell Research — Tue, 27 Dec 2011 05:00:00 +0100

Authors: Kang HN, Oh SC, Kim JS, Yoo YA Abstract p53, the major human tumor suppressor, appears to be related to sonic hedgehog (Shh)-Gli-mediated tumorigenesis. However, the role of p53 in tumor progression by the Shh-Gli signaling pathway is poorly understood. Herein we investigated the critical regulation of Gli3-p53 in tumorigenesis of colon cancer cells and the molecular mechanisms underlying these effects. RT-PCR analysis indicated that the mRNA level of Shh and Gli3 in colon tumor tissues was significantly higher than corresponding normal tissues (P<0.001). The inhibition of Gli3 by treatment with Gli3 siRNA resulted in a clear decrease in cell proliferation and enhanced the level of expression of p53 proteins compared to treatment with control siRNA. The half-life of p53...

Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo

Breast Cancer Research and Treatment — Mon, 26 Dec 2011 16:45:50 +0100

Abstract In preclinical models, the histone deacetylase inhibitor vorinostat sensitizes breast cancer cells to tubulin-polymerizing agents and to anti-vascular endothelial growth factor-directed therapies. We sought to determine the safety and efficacy of vorinostat plus paclitaxel and bevacizumab as first-line therapy in metastatic breast cancer (MBC), and the biological effects of vorinostat in vivo. For this purpose of this study, 54 patients with measurable disease and no prior chemotherapy for MBC received vorinostat (200 or 300 mg PO BID) on days 1–3, 8–10, and 15–17, plus paclitaxel (90 mg/m2) on days 2, 9, 16, and bevacizumab (10 mg/kg) on days 2 and 16 every 28 days. The primary objective of the phase I study was to determine the recommend...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer

Breast Cancer Research and Treatment — Mon, 26 Dec 2011 16:45:50 +0100

Abstract Bevacizumab in combination with chemotherapy increases progression-free survival (PFS), but not overall survival when compared to chemotherapy alone in the treatment of metastatic breast cancer (MBC). Recently in November, 2011 the Food and drug administration revoked approval of bevacizumab in combination with paclitaxel for the treatment of MBC. The European Medicines Agency, in contrast, maintained its approval of bevacizumab in MBC. While neither agency considers health economics in their decision-making process, one of the greatest challenges in oncology practice today is to reconcile hard-won small incremental clinical benefits with exponentially rising costs. To inform policy-makers in the US, this study aimed to assess the cost-effectiveness of bevacizumab/...

Bevacizumab Reduces Nasopharyngeal Carcinoma Spread - Trial Finds

Health News from Medical News Today — Mon, 26 Dec 2011 08:00:00 +0100

According to a new phase 2 trial published Online First in The Lancet Oncology, the combination of the widely used anti-cancer drug bevacizumab with standard chemo-radiation therapy is safe, and could prolong survival in patients with advanced nasopharyngeal carcinoma, without any apparent increased adverse side effects. The results of the RTOG 0615 trial, conducted by the Radiation Therapy Oncology Group (RTOG), suggest that bevacizumab might be more effective at preventing the spread of nasopharyngeal carcinoma to other parts of the body... (Source: Health News from Medical News Today)

Roche's Avastin Receives EU Approval For Ovarian Cancer

Health News from Medical News Today — Sat, 24 Dec 2011 12:00:00 +0100

Roche announced today that its product known as Avastin (bevacizumab) has been approved by the European Union for treatment of ovarian cancer. When used in combination with standard chemotherapy (carboplatin and paclitaxel) it will be part of a front-line (first-line following surgery) regime. Hal Barron M.D., Chief Medical Officer and Head, Global Product Development said : "Today's approval of Avastin marks the first major treatment advance in newly diagnosed ovarian cancer in 15 years ... (Source: Health News from Medical News Today)

EU OKs Roche's Avastin (bevacizumab) for ovarian cancer

Modern Medicine — Sat, 24 Dec 2011 05:00:00 +0100

ZURICH (Reuters) - The European Commission has approved Roche's drug Avastin (bevacizumab) for treating newly diagnosed, advanced ovarian cancer, offering new options to sufferers previously limited to surgery and chemotherapy. (Source: Modern Medicine)